Condition
Stage IVA Gallbladder Cancer AJCC v7
Total Trials
4
Recruiting
0
Active
1
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
3 of 3 completed with results
Key Signals
3 with results100% success
Data Visualizations
Phase Distribution
4Total
P 1 (1)
P 2 (3)
Trial Status
Completed3
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT03257761Phase 1Active Not Recruiting
Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer
NCT03278106Phase 2Completed
TAS-102 in Treating Advanced Biliary Tract Cancers
NCT02520141Phase 2Completed
Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery
NCT02392637Phase 2Completed
Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers
Showing all 4 trials